-
1.发明申请Pharmaceutical Compositions for Treatment of HCV Patients that are Poor-Responders to Interferon 有权用于治疗HCV干扰素不良反应者的药物组合物公开(公告)号：US20100330035A1
公开(公告)日：2010-12-30
申请号：US12767631
申请日：2010-04-26
申请人： Elisabeth S. HILDEBRANDT-ERIKSEN , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
发明人： Elisabeth S. HILDEBRANDT-ERIKSEN , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
IPC分类号： A61K38/21 , A61K31/7088 , A61P31/14 , C12N5/071
CPC分类号： C12N15/1131 , A61K31/7105 , C12N2310/113 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3521 , C12N2310/3525 , C12N2310/3533
摘要： The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
摘要翻译： 本发明提供对干扰素治疗不敏感的HCV感染受试者的治疗组合物和方法。 此外，提供了用于预防器官移植排斥的组合物和方法。 本发明的组合物包含抗微小RNA-122寡核苷酸，并且制备用于给予灵长类动物。
-
2.发明授权Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon 有权用于治疗干扰素反应不良的HCV患者的药物组合物公开(公告)号：US09034837B2
公开(公告)日：2015-05-19
申请号：US12767631
申请日：2010-04-26
申请人： Elisabeth S. Hildebrandt-Eriksen , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
发明人： Elisabeth S. Hildebrandt-Eriksen , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , A61K31/7105 , C12N15/113
CPC分类号： C12N15/1131 , A61K31/7105 , C12N2310/113 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3521 , C12N2310/3525 , C12N2310/3533
摘要： The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
摘要翻译： 本发明提供对干扰素治疗不敏感的HCV感染受试者的治疗组合物和方法。 此外，提供了用于预防器官移植排斥的组合物和方法。 本发明的组合物包含抗微小RNA-122寡核苷酸，并且制备用于给予灵长类动物。
-
3.发明授权公开(公告)号：US08404659B2
公开(公告)日：2013-03-26
申请号：US12921339
申请日：2009-03-09
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , C12N2310/141
摘要： The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.
摘要翻译： 本发明提供治疗对下调微小RNA，mRNA，非编码RNA或病毒基因组的功能的药物敏感的疾病的组合物和方法。 特别地，已经发现，当给予灵长类动物时，可以获得抗微小RNA寡核苷酸的非常长的效果。 因此，本发明涉及用于治疗灵长类动物的药物组合物和方法，包括人，其中组合物以长时间间隔施用。
-
-
搜索结果
3 条记录 (耗时 0.026 秒)
